|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar
|
|
2
|
Siegel RL, Ward EM and Jemal A: Trends in
colorectal cancer incidence rates in the United States by tumor
location and stage, 1992–2008. Cancer Epidemiol Biomarkers Prev.
21:411–416. 2012.PubMed/NCBI
|
|
3
|
Zanders MM, Vissers PA, Haak HR and van de
Poll-Franse LV: Colorectal cancer, diabetes and survival:
epidemiological insights. Diabetes Metab. 40:120–127. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Jawad N, Direkze N and Leedham SJ:
Inflammatory bowel disease and colon cancer. Recent Results Cancer
Res. 185:99–115. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: the next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Andersen NN and Jess T: Has the risk of
colorectal cancer in inflammatory bowel disease decreased? World J
Gastroenterol. 19:7561–7568. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Aggarwal BB, Kunnumakkara AB, Harikumar
KB, et al: Signal transducer and activator of transcription-3,
inflammation, and cancer: how intimate is the relationship? Ann NY
Acad Sci. 1171:59–76. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lin Q, Lai R, Chirieac LR, et al:
Constitutive activation of JAK3/STAT3 in colon carcinoma tumors and
cell lines: inhibition of JAK3/STAT3 signaling induces apoptosis
and cell cycle arrest of colon carcinoma cells. Am J Pathol.
167:969–980. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Knüpfer H and Preiss R: Serum
interleukin-6 levels in colorectal cancer patients - a summary of
published results. Int J Colorectal Dis. 25:135–140.
2010.PubMed/NCBI
|
|
10
|
Morikawa T, Baba Y, Yamauchi M, et al:
STAT3 expression, molecular features, inflammation patterns, and
prognosis in a database of 724 colorectal cancers. Clin Cancer Res.
17:1452–1462. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wang SW and Sun YM: The IL-6/JAK/STAT3
pathway: Potential therapeutic strategies in treating colorectal
cancer (Review). Int J Oncol. 44:1032–1040. 2014.PubMed/NCBI
|
|
12
|
McFarland BC, Ma JY, Langford CP, et al:
Therapeutic potential of AZD1480 for the treatment of human
glioblastoma. Mol Cancer Ther. 10:2384–2393. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Scuto A, Krejci P, Popplewell L, et al:
The novel JAK inhibitor AZD1480 blocks STAT3 and FGFR3 signaling,
resulting in suppression of human myeloma cell growth and survival.
Leukemia. 25:538–550. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Liu Y, Holdbrooks AT, De Sarno P, et al:
Therapeutic efficacy of suppressing the Jak/STAT pathway in
multiple models of experimental autoimmune encephalomyelitis. J
Immunol. 192:59–72. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Murakami T, Takigawa N, Ninomiya T, et al:
Effect of AZD1480 in an epidermal growth factor receptor-driven
lung cancer model. Lung Cancer. 83:30–36. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Stuart E, Buchert M, Putoczki T, et al:
Therapeutic inhibition of jak activity inhibits progression of
gastrointestinal tumors in mice. Mol Cancer Ther. 13:468–474. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yang X, Zhang F, Wang Y, et al: Oroxylin A
inhibits colitis-associated carcinogenesis through modulating the
IL-6/STAT3 signaling pathway. Inflamm Bowel Dis. 19:1990–2000.
2013.PubMed/NCBI
|
|
18
|
Li GH, Wei H, Lv SQ, Ji H and Wang DL:
Knockdown of STAT3 expression by RNAi suppresses growth and induces
apoptosis and differentiation in glioblastoma stem cells. Int J
Oncol. 37:103–110. 2010.PubMed/NCBI
|
|
19
|
Guthrie GJ, Roxburgh CS, Horgan PG and
McMillan DC: Does interleukin-6 link explain the link between
tumour necrosis, local and systemic inflammatory responses and
outcome in patients with colorectal cancer? Cancer Treat Rev.
39:89–96. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sakamoto K and Maeda S: Targeting NF-κB
for colorectal cancer. Expert Opin Ther Targets. 14:593–601.
2010.
|
|
21
|
Hoesel B and Schmid JA: The complexity of
NF-κB signaling in inflammation and cancer. Mol Cancer.
12:862013.
|
|
22
|
Taniguchi K and Karin M: IL-6 and related
cytokines as the critical lynchpins between inflammation and
cancer. Semin Immunol. 26:54–74. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Putoczki TL, Thiem S, Loving A, et al:
Interleukin-11 is the dominant IL-6 family cytokine during
gastrointestinal tumorigenesis and can be targeted therapeutically.
Cancer Cell. 24:257–271. 2013. View Article : Google Scholar
|
|
24
|
Gordziel C, Bratsch J, Moriggl R, Knösel T
and Friedrich K: Both STAT1 and STAT3 are favourable prognostic
determinants in colorectal carcinoma. Br J Cancer. 109:138–146.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Gu L, Talati P, Vogiatzi P, et al:
Pharmacologic suppression of JAK1/2 by JAK1/2 inhibitor AZD1480
potently inhibits IL-6-induced experimental prostate cancer
metastases formation. Mol Cancer Ther. 13:1246–1258. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Furqan M, Mukhi N, Lee B and Liu D:
Dysregulation of JAK-STAT pathway in hematological malignancies and
JAK inhibitors for clinical application. Biomark Res. 1:52013.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lee JH, Park KS, Alberobello AT, et al:
The Janus kinases inhibitor AZD1480 attenuates growth of small cell
lung cancers in vitro and in vivo. Clin Cancer Res. 19:6777–6786.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yan S, Li Z and Thiele CJ: Inhibition of
STAT3 with orally active JAK inhibitor, AZD1480, decreases tumor
growth in neuroblastoma and pediatric sarcomas in vitro and in
vivo. Oncotarget. 4:433–445. 2013.PubMed/NCBI
|
|
29
|
Xiong H, Su WY, Liang QC, et al:
Inhibition of STAT5 induces G1 cell cycle arrest and reduces tumor
cell invasion in human colorectal cancer cells. Lab Invest.
89:717–725. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Xiong H, Zhang ZG, Tian XQ, et al:
Inhibition of JAK1, 2/STAT3 signaling induces apoptosis, cell cycle
arrest, and reduces tumor cell invasion in colorectal cancer cells.
Neoplasia. 10:287–297. 2008.PubMed/NCBI
|
|
31
|
Fletcher S, Drewry JA, Shahani VM, Page BD
and Gunning PT: Molecular disruption of oncogenic signal transducer
and activator of transcription 3 (STAT3) protein. Biochem Cell
Biol. 87:825–833. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
32
|
Hedvat M, Huszar D, Herrmann A, et al: The
JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and
oncogenesis in solid tumors. Cancer Cell. 16:487–497. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Reddy MM, Deshpande A and Sattler M:
Targeting JAK2 in the therapy of myeloproliferative neoplasms.
Expert Opin Ther Targets. 16:313–324. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Tibes R, Bogenberger JM, Geyer HL and Mesa
RA: JAK2 inhibitors in the treatment of myeloproliferative
neoplasms. Expert Opin Investig Drugs. 21:1755–1774. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Nadiminty N, Lou W, Lee SO, Lin X, Trump
DL and Gao AC: Stat3 activation of NF-κB p100 processing involves
CBP/p300-mediated acetylation. Proc Natl Acad Sci USA.
103:7264–7269. 2006.
|
|
36
|
Yang J, Liao X, Agarwal MK, Barnes L,
Auron PE and Stark GR: Unphosphorylated STAT3 accumulates in
response to IL-6 and activates transcription by binding to NFκB.
Genes Dev. 21:1396–1408. 2007.PubMed/NCBI
|
|
37
|
Grivennikov S, Karin E, Terzic J, et al:
IL-6 and Stat3 are required for survival of intestinal epithelial
cells and development of colitis-associated cancer. Cancer Cell.
15:103–113. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Grivennikov S and Karin M: Autocrine IL-6
signaling: a key event in tumorigenesis? Cancer Cell. 13:7–9. 2008.
View Article : Google Scholar : PubMed/NCBI
|
